Pioglitazone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pioglitazone" in English language version.

refsWebsite

Global rank English rank

29nih.gov

4^th place

18doi.org

2^nd place

15web.archive.org

1^st place

6semanticscholar.org

11^th place

8^th place

4fda.gov

447^th place

338^th place

2europa.eu

68^th place

117^th place

2books.google.com

3^rd place

2clincalc.com

3,912^th place

2,496^th place

1drugs.com

399^th place

333^rd place

1ulg.ac.be

7,875^th place

8,199^th place

1handle.net

102^nd place

76^th place

1lefigaro.fr

113^th place

775^th place

1medical-reference.net

low place

1reuters.com

49^th place

47^th place

1harvard.edu

18^th place

17^th place

1drugpatentwatch.com

low place

1escholarship.org

1,523^rd place

976^th place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 450. ISBN 9783527607495. Archived from the original on 21 December 2020. Retrieved 23 September 2020.
Burant C (2012). Medical Management of Type 2 Diabetes. American Diabetes Association. p. 63. ISBN 9781580404570. Archived from the original on 28 January 2021. Retrieved 23 September 2020.

clincalc.com

"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"Pioglitazone - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

doi.org

Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, et al. (Cochrane Metabolic and Endocrine Disorders Group) (November 2020). "Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews. 2020 (11): CD013516. doi:10.1002/14651858.CD013516.pub2. PMC 8092670. PMID 33210751.
Scheen AJ (November 2012). "Outcomes and lessons from the PROactive study". Diabetes Research and Clinical Practice. 98 (2): 175–86. doi:10.1016/j.diabres.2012.09.001. hdl:2268/132794. PMID 23020930. Archived from the original on 28 January 2021. Retrieved 18 September 2019. Since 2005, there has been much debate on the relative value of the statistically non-significant 10% reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with pioglitazone.
Strongman H, Korhonen P, Williams R, et al. (2017). "Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study". BMJ Open Diabetes Research & Care. 5 (1): e000364. doi:10.1136/bmjdrc-2016-000364. PMC 5530248. PMID 28761650.
Yang J, Vallarino C, Bron M, Perez A, Liang H, Joseph G, et al. (2014). "A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study". Current Medical Research and Opinion. 30 (11): 2223–2231. doi:10.1185/03007995.2014.941054. PMID 24983744. S2CID 35665797.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (September 2007). "Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials". JAMA. 298 (10): 1180–8. doi:10.1001/jama.298.10.1180. PMID 17848652.
Filipova E, Uzunova K, Kalinov K, Vekov T (August 2017). "Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis". Diabetes Therapy. 8 (4): 705–726. doi:10.1007/s13300-017-0273-4. PMC 5544610. PMID 28623552.
Gillies PS, Dunn CJ (August 2000). "Pioglitazone". Drugs. 60 (2): 333–43, discussion 344–5. doi:10.2165/00003495-200060020-00009. PMID 10983737. S2CID 265781287.
Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, et al. (February 2004). "Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe". American Journal of Physiology. Endocrinology and Metabolism. 286 (2): E252–60. doi:10.1152/ajpendo.00424.2003. PMID 14570702. S2CID 20550873.
Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, et al. (September 2007). "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone". Proceedings of the National Academy of Sciences of the United States of America. 104 (36): 14342–7. Bibcode:2007PNAS..10414342P. doi:10.1073/pnas.0707189104. PMC 1963346. PMID 17766440.
Monternier PA, Singh J, Parasar P, Theurey P, DeWitt S, Jacques V, et al. (July 2022). "Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy". Journal of Inherited Metabolic Disease. 45 (4): 832–847. doi:10.1002/jimd.12510. PMC 9545763. PMID 35510808.
Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (September 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090. S2CID 237485915.
Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, et al. (2017). "Pioglitazone could induce remission in major depression: a meta-analysis". Neuropsychiatric Disease and Treatment. 13: 9–16. doi:10.2147/NDT.S121149. PMC 5182046. PMID 28031713.
Jafari M, Khodayari B, Felgner J, Bussel II, Rose MR, Mueller LD (December 2007). "Pioglitazone: an anti-diabetic compound with anti-aging properties" (PDF). Biogerontology. 8 (6): 639–51. doi:10.1007/s10522-007-9105-7. PMID 17628757. S2CID 9714773.
Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. (March 2022). "Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss". BMC Endocrine Disorders. 22 (1): 63. doi:10.1186/s12902-022-00980-1. PMC 8919523. PMID 35287643.
Doyle CA, McDougle CJ (August 2012). "Pharmacotherapy to control behavioral symptoms in children with autism". Expert Opinion on Pharmacotherapy. 13 (11): 1615–29. doi:10.1517/14656566.2012.674110. PMID 22550944. S2CID 32144885.
Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC (2010). "Lipid disturbances in psoriasis: an update". Mediators of Inflammation. 2010: 535612. doi:10.1155/2010/535612. PMC 2914266. PMID 20706605.
Abyadeh M, Gupta V, Gupta V, Chitranshi N, Wu Y, Amirkhani A, et al. (December 2021). "Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease". Aging and Disease. 12 (8): 1964–1976. doi:10.14336/AD.2021.0719. PMC 8612603. PMID 34881080.
de Guglielmo G, Kallupi M, Scuppa G, Demopulos G, Gaitanaris G, Ciccocioppo R (January 2017). "Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents". Psychopharmacology. 234 (2): 223–234. doi:10.1007/s00213-016-4452-1. PMID 27714428.

drugpatentwatch.com

"Details for Actos". Drug Patent Watch. Archived from the original on 15 August 2011. Retrieved 14 December 2009.

drugs.com

"Pioglitazone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 15 August 2020. Retrieved 3 March 2019.

escholarship.org

Jafari M, Khodayari B, Felgner J, Bussel II, Rose MR, Mueller LD (December 2007). "Pioglitazone: an anti-diabetic compound with anti-aging properties" (PDF). Biogerontology. 8 (6): 639–51. doi:10.1007/s10522-007-9105-7. PMID 17628757. S2CID 9714773.

europa.eu

ema.europa.eu

"Actos EPAR". European Medicines Agency (EMA). 13 October 2000. Retrieved 27 August 2024.
"Update on ongoing European review of pioglitazone–containing medicines". European Medicines Agency (EMA) (Press release). Archived from the original on 22 October 2020. Retrieved 8 November 2020.

fda.gov

"Update to ongoing safety review of Actos". U.S. Food and Drug Administration. 18 June 2019. Archived from the original on 28 September 2020. Retrieved 8 November 2020.
"Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with ACTOSO (pioglitazone HOI) Tablets for Type 2 Diabetes Mellitus" (PDF). Takeda. Food and Drug Administration. March 2007. Archived from the original (PDF) on 16 May 2012. Retrieved 4 April 2012.
"FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines". U.S. Food and Drug Administration (FDA). 4 August 2011. Archived from the original on 24 April 2019. Retrieved 16 December 2019.
"FDA approves first generic Actos to treat type 2 diabetes" (Press release). U.S. Food and Drug Administration (FDA). 17 August 2012. Archived from the original on 4 January 2016.

handle.net

hdl.handle.net

Scheen AJ (November 2012). "Outcomes and lessons from the PROactive study". Diabetes Research and Clinical Practice. 98 (2): 175–86. doi:10.1016/j.diabres.2012.09.001. hdl:2268/132794. PMID 23020930. Archived from the original on 28 January 2021. Retrieved 18 September 2019. Since 2005, there has been much debate on the relative value of the statistically non-significant 10% reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with pioglitazone.

harvard.edu

ui.adsabs.harvard.edu

Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, et al. (September 2007). "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone". Proceedings of the National Academy of Sciences of the United States of America. 104 (36): 14342–7. Bibcode:2007PNAS..10414342P. doi:10.1073/pnas.0707189104. PMC 1963346. PMID 17766440.

lefigaro.fr

"L'antidiabétique Actos retiré du marché" [Actos antidiabetic withdrawn from the market]. Le Figaro (in French). 9 June 2011. Archived from the original on 12 June 2011. Retrieved 9 June 2011.

medical-reference.net

Alam II (1 January 2012). "France and Germany Suspended Use of Actos for Bladder Cancer Risk". Medical-Reference. Archived from the original on 2 September 2012. Retrieved 27 August 2012.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, et al. (Cochrane Metabolic and Endocrine Disorders Group) (November 2020). "Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews. 2020 (11): CD013516. doi:10.1002/14651858.CD013516.pub2. PMC 8092670. PMID 33210751.
Scheen AJ (November 2012). "Outcomes and lessons from the PROactive study". Diabetes Research and Clinical Practice. 98 (2): 175–86. doi:10.1016/j.diabres.2012.09.001. hdl:2268/132794. PMID 23020930. Archived from the original on 28 January 2021. Retrieved 18 September 2019. Since 2005, there has been much debate on the relative value of the statistically non-significant 10% reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with pioglitazone.
Strongman H, Korhonen P, Williams R, et al. (2017). "Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study". BMJ Open Diabetes Research & Care. 5 (1): e000364. doi:10.1136/bmjdrc-2016-000364. PMC 5530248. PMID 28761650.
Yang J, Vallarino C, Bron M, Perez A, Liang H, Joseph G, et al. (2014). "A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study". Current Medical Research and Opinion. 30 (11): 2223–2231. doi:10.1185/03007995.2014.941054. PMID 24983744. S2CID 35665797.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (September 2007). "Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials". JAMA. 298 (10): 1180–8. doi:10.1001/jama.298.10.1180. PMID 17848652.
Filipova E, Uzunova K, Kalinov K, Vekov T (August 2017). "Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis". Diabetes Therapy. 8 (4): 705–726. doi:10.1007/s13300-017-0273-4. PMC 5544610. PMID 28623552.
Gillies PS, Dunn CJ (August 2000). "Pioglitazone". Drugs. 60 (2): 333–43, discussion 344–5. doi:10.2165/00003495-200060020-00009. PMID 10983737. S2CID 265781287.
Smith U (September 2001). "Pioglitazone: mechanism of action". International Journal of Clinical Practice. Supplement (121): 13–8. PMID 11594239.
Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, et al. (February 2004). "Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe". American Journal of Physiology. Endocrinology and Metabolism. 286 (2): E252–60. doi:10.1152/ajpendo.00424.2003. PMID 14570702. S2CID 20550873.
Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, et al. (September 2007). "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone". Proceedings of the National Academy of Sciences of the United States of America. 104 (36): 14342–7. Bibcode:2007PNAS..10414342P. doi:10.1073/pnas.0707189104. PMC 1963346. PMID 17766440.
Monternier PA, Singh J, Parasar P, Theurey P, DeWitt S, Jacques V, et al. (July 2022). "Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy". Journal of Inherited Metabolic Disease. 45 (4): 832–847. doi:10.1002/jimd.12510. PMC 9545763. PMID 35510808.
Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (September 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090. S2CID 237485915.
Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, et al. (2017). "Pioglitazone could induce remission in major depression: a meta-analysis". Neuropsychiatric Disease and Treatment. 13: 9–16. doi:10.2147/NDT.S121149. PMC 5182046. PMID 28031713.
Jafari M, Khodayari B, Felgner J, Bussel II, Rose MR, Mueller LD (December 2007). "Pioglitazone: an anti-diabetic compound with anti-aging properties" (PDF). Biogerontology. 8 (6): 639–51. doi:10.1007/s10522-007-9105-7. PMID 17628757. S2CID 9714773.
Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. (March 2022). "Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss". BMC Endocrine Disorders. 22 (1): 63. doi:10.1186/s12902-022-00980-1. PMC 8919523. PMID 35287643.
Doyle CA, McDougle CJ (August 2012). "Pharmacotherapy to control behavioral symptoms in children with autism". Expert Opinion on Pharmacotherapy. 13 (11): 1615–29. doi:10.1517/14656566.2012.674110. PMID 22550944. S2CID 32144885.
Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC (2010). "Lipid disturbances in psoriasis: an update". Mediators of Inflammation. 2010: 535612. doi:10.1155/2010/535612. PMC 2914266. PMID 20706605.
Abyadeh M, Gupta V, Gupta V, Chitranshi N, Wu Y, Amirkhani A, et al. (December 2021). "Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease". Aging and Disease. 12 (8): 1964–1976. doi:10.14336/AD.2021.0719. PMC 8612603. PMID 34881080.
de Guglielmo G, Kallupi M, Scuppa G, Demopulos G, Gaitanaris G, Ciccocioppo R (January 2017). "Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents". Psychopharmacology. 234 (2): 223–234. doi:10.1007/s00213-016-4452-1. PMID 27714428.

ncbi.nlm.nih.gov

Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, et al. (Cochrane Metabolic and Endocrine Disorders Group) (November 2020). "Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews. 2020 (11): CD013516. doi:10.1002/14651858.CD013516.pub2. PMC 8092670. PMID 33210751.
Strongman H, Korhonen P, Williams R, et al. (2017). "Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study". BMJ Open Diabetes Research & Care. 5 (1): e000364. doi:10.1136/bmjdrc-2016-000364. PMC 5530248. PMID 28761650.
Filipova E, Uzunova K, Kalinov K, Vekov T (August 2017). "Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis". Diabetes Therapy. 8 (4): 705–726. doi:10.1007/s13300-017-0273-4. PMC 5544610. PMID 28623552.
Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, et al. (September 2007). "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone". Proceedings of the National Academy of Sciences of the United States of America. 104 (36): 14342–7. Bibcode:2007PNAS..10414342P. doi:10.1073/pnas.0707189104. PMC 1963346. PMID 17766440.
Monternier PA, Singh J, Parasar P, Theurey P, DeWitt S, Jacques V, et al. (July 2022). "Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy". Journal of Inherited Metabolic Disease. 45 (4): 832–847. doi:10.1002/jimd.12510. PMC 9545763. PMID 35510808.
Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, et al. (2017). "Pioglitazone could induce remission in major depression: a meta-analysis". Neuropsychiatric Disease and Treatment. 13: 9–16. doi:10.2147/NDT.S121149. PMC 5182046. PMID 28031713.
Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. (March 2022). "Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss". BMC Endocrine Disorders. 22 (1): 63. doi:10.1186/s12902-022-00980-1. PMC 8919523. PMID 35287643.
Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC (2010). "Lipid disturbances in psoriasis: an update". Mediators of Inflammation. 2010: 535612. doi:10.1155/2010/535612. PMC 2914266. PMID 20706605.
Abyadeh M, Gupta V, Gupta V, Chitranshi N, Wu Y, Amirkhani A, et al. (December 2021). "Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease". Aging and Disease. 12 (8): 1964–1976. doi:10.14336/AD.2021.0719. PMC 8612603. PMID 34881080.

dailymed.nlm.nih.gov

"Actos- pioglitazone tablet". DailyMed. 25 January 2019. Archived from the original on 6 September 2015. Retrieved 13 February 2020.

reuters.com

Topham J (10 June 2011). "UPDATE 2-Germany joins France in suspending top Takeda drug". Reuters. Archived from the original on 13 November 2015. Retrieved 1 July 2017.

semanticscholar.org

api.semanticscholar.org

Yang J, Vallarino C, Bron M, Perez A, Liang H, Joseph G, et al. (2014). "A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study". Current Medical Research and Opinion. 30 (11): 2223–2231. doi:10.1185/03007995.2014.941054. PMID 24983744. S2CID 35665797.
Gillies PS, Dunn CJ (August 2000). "Pioglitazone". Drugs. 60 (2): 333–43, discussion 344–5. doi:10.2165/00003495-200060020-00009. PMID 10983737. S2CID 265781287.
Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, et al. (February 2004). "Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe". American Journal of Physiology. Endocrinology and Metabolism. 286 (2): E252–60. doi:10.1152/ajpendo.00424.2003. PMID 14570702. S2CID 20550873.
Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (September 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090. S2CID 237485915.
Jafari M, Khodayari B, Felgner J, Bussel II, Rose MR, Mueller LD (December 2007). "Pioglitazone: an anti-diabetic compound with anti-aging properties" (PDF). Biogerontology. 8 (6): 639–51. doi:10.1007/s10522-007-9105-7. PMID 17628757. S2CID 9714773.
Doyle CA, McDougle CJ (August 2012). "Pharmacotherapy to control behavioral symptoms in children with autism". Expert Opinion on Pharmacotherapy. 13 (11): 1615–29. doi:10.1517/14656566.2012.674110. PMID 22550944. S2CID 32144885.

ulg.ac.be

orbi.ulg.ac.be

Scheen AJ (November 2012). "Outcomes and lessons from the PROactive study". Diabetes Research and Clinical Practice. 98 (2): 175–86. doi:10.1016/j.diabres.2012.09.001. hdl:2268/132794. PMID 23020930. Archived from the original on 28 January 2021. Retrieved 18 September 2019. Since 2005, there has been much debate on the relative value of the statistically non-significant 10% reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with pioglitazone.

web.archive.org

"Actos- pioglitazone tablet". DailyMed. 25 January 2019. Archived from the original on 6 September 2015. Retrieved 13 February 2020.
"Pioglitazone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 15 August 2020. Retrieved 3 March 2019.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 450. ISBN 9783527607495. Archived from the original on 21 December 2020. Retrieved 23 September 2020.
"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
Burant C (2012). Medical Management of Type 2 Diabetes. American Diabetes Association. p. 63. ISBN 9781580404570. Archived from the original on 28 January 2021. Retrieved 23 September 2020.
"Update to ongoing safety review of Actos". U.S. Food and Drug Administration. 18 June 2019. Archived from the original on 28 September 2020. Retrieved 8 November 2020.
"Update on ongoing European review of pioglitazone–containing medicines". European Medicines Agency (EMA) (Press release). Archived from the original on 22 October 2020. Retrieved 8 November 2020.
Scheen AJ (November 2012). "Outcomes and lessons from the PROactive study". Diabetes Research and Clinical Practice. 98 (2): 175–86. doi:10.1016/j.diabres.2012.09.001. hdl:2268/132794. PMID 23020930. Archived from the original on 28 January 2021. Retrieved 18 September 2019. Since 2005, there has been much debate on the relative value of the statistically non-significant 10% reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with pioglitazone.
"Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with ACTOSO (pioglitazone HOI) Tablets for Type 2 Diabetes Mellitus" (PDF). Takeda. Food and Drug Administration. March 2007. Archived from the original (PDF) on 16 May 2012. Retrieved 4 April 2012.
"L'antidiabétique Actos retiré du marché" [Actos antidiabetic withdrawn from the market]. Le Figaro (in French). 9 June 2011. Archived from the original on 12 June 2011. Retrieved 9 June 2011.
Alam II (1 January 2012). "France and Germany Suspended Use of Actos for Bladder Cancer Risk". Medical-Reference. Archived from the original on 2 September 2012. Retrieved 27 August 2012.
Topham J (10 June 2011). "UPDATE 2-Germany joins France in suspending top Takeda drug". Reuters. Archived from the original on 13 November 2015. Retrieved 1 July 2017.
"FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines". U.S. Food and Drug Administration (FDA). 4 August 2011. Archived from the original on 24 April 2019. Retrieved 16 December 2019.
"Details for Actos". Drug Patent Watch. Archived from the original on 15 August 2011. Retrieved 14 December 2009.
"FDA approves first generic Actos to treat type 2 diabetes" (Press release). U.S. Food and Drug Administration (FDA). 17 August 2012. Archived from the original on 4 January 2016.